<div id="readability-page-1"><div> By Katherine Hamilton <pre></pre> Micron Technology recorded a jump in sales and raised some of its expectations for demand growth in coming months. The stock gained 7.7%, to $242.86, in after-hours trading Wednesday. MillerKnoll's third-quarter forecast was ahead of Wall Street estimates. Shares rose 8.7%, to $19.05, after the bell. HireQuest authorized a $20 million share-buyback program. The stock rose 5%, to $8.12. Insmed said it would discontinue the development of its treatment for rhinosinusitis after the drug failed to meet primary and secondary endpoints. Shares slid 19%, to $160.18. <pre></pre> Write to Katherine Hamilton at katherine.hamilton@wsj.com <pre></pre> (END) Dow Jones Newswires December 17, 2025 18:50 ET (23:50 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

INSM

MLKN

Micron Technology's sales increase led to a 7.7% stock rise. MillerKnoll's forecast exceeded expectations, boosting shares by 8.7%. HireQuest announced a $20 million share-buyback, raising stock by 5%. Insmed discontinued a drug development, causing shares to drop 19%.

- Micron Technology experienced a rise in sales and increased its demand growth expectations, with its stock gaining 7.7% to $242.86.  
- MillerKnoll's third-quarter forecast exceeded Wall Street estimates, leading to an 8.7% stock increase to $19.05.  
- Insmed announced the discontinuation of its rhinosinusitis treatment after it failed to meet trial endpoints, resulting in a 19% drop in shares to $160.18.

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed